公开(公告)号：US20060035878A1

公开(公告)日：2006-02-16

申请号：US10518870

申请日：2003-06-19

申请人： Masayoshi Shichiri ,  Yujiro Tanaka

发明人： Masayoshi Shichiri ,  Yujiro Tanaka

IPC分类号： A61K31/33

CPC分类号： A61K31/395 ,  A61K31/496 ,  G01N33/5011

摘要： The present invention provides novel angiogenesis inhibitors effective, safe and highly practical for inhibition of angiogenesis in various diseases, and a method for screening the same. The active ingredients of the angiogenesis inhibitors of the present invention comprise ansamycin antibiotics such as rifampicin, rifamycin SV and 3-formyl rifamycin, which have long been used extensively as antibacterial agents for treating tuberculosis or Gram-positive bacterial infections. The active ingredients of the present invention have excellent angiogenesis-inhibiting activity. The angiogenesis inhibitor of the present invention is effective for inhibition of angiogenesis in malignant tumors, diabetic retinopathy, retinal angiogenesis, inflammatory diseases, and angiogenesis accompanying cardiovascular remodeling, etc., and can be used as therapeutic agents against each disease, etc. Further, the screening method of the present invention makes it possible to perform an effective screening of angiogenesis-inhibiting substances by detecting angiogenesis-inhibiting signals based on gene expression levels.

摘要翻译： 本发明提供了用于抑制各种疾病中的血管发生的有效，安全和高度实用的新型血管生成抑制剂及其筛选方法。 本发明的血管发生抑制剂的活性成分包括长时久以来被广泛用作治疗结核病或革兰氏阳性细菌感染的抗菌剂的安莎霉素抗生素如利福平，利福霉素SV和3-甲酰基利福霉素。 本发明的活性成分具有优异的血管生成抑制活性。 本发明的血管生成抑制剂对于抑制恶性肿瘤，糖尿病性视网膜病变，视网膜血管生成，炎症性疾病以及伴随心血管重塑等的血管发生等，对于抑制血管生成有效，可用作针对各种疾病的治疗剂等。另外， 通过本发明的筛选方法，可以通过基于基因表达水平检测血管生成抑制信号来进行血管新生抑制物质的有效筛选。

公开(公告)号：US20100004327A1

公开(公告)日：2010-01-07

申请号：US12504823

申请日：2009-07-17

申请人： Masayoshi Shichiri ,  Yujiro Tanaka

发明人： Masayoshi Shichiri ,  Yujiro Tanaka

IPC分类号： A61K31/395

CPC分类号： A61K31/395 ,  A61K31/496 ,  G01N33/5011

摘要： The present invention provides novel angiogenesis inhibitors effective, safe and highly practical for inhibition of angiogenesis in various diseases, and a method for screening the same. The active ingredients of the angiogenesis inhibitors of the present invention comprise ansamycin antibiotics such as rifampicin, rifamycin SV and 3-formyl rifamycin, which have long been used extensively as antibacterial agents for treating tuberculosis or Gram-positive bacterial infections. The active ingredients of the present invention have excellent angiogenesis-inhibiting activity. The angiogenesis inhibitor of the present invention is effective for inhibition of angiogenesis in malignant tumors, diabetic retinopathy, retinal angiogenesis, inflammatory diseases, and angiogenesis accompanying cardiovascular remodeling, etc., and can be used as therapeutic agents against each disease, etc. Further, the screening method of the present invention makes it possible to perform an effective screening of angiogenesis-inhibiting substances by detecting angiogenesis-inhibiting signals based on gene expression levels.

摘要翻译： 本发明提供了用于抑制各种疾病中的血管发生的有效，安全和高度实用的新型血管生成抑制剂及其筛选方法。 本发明的血管发生抑制剂的活性成分包括长时久以来被广泛用作治疗结核病或革兰氏阳性细菌感染的抗菌剂的安莎霉素抗生素如利福平，利福霉素SV和3-甲酰基利福霉素。 本发明的活性成分具有优异的血管生成抑制活性。 本发明的血管生成抑制剂对于抑制恶性肿瘤，糖尿病性视网膜病变，视网膜血管生成，炎症性疾病以及伴随心血管重塑等的血管发生等，对于抑制血管生成有效，可用作针对各种疾病的治疗剂等。另外， 通过本发明的筛选方法，可以通过基于基因表达水平检测血管生成抑制信号来进行血管新生抑制物质的有效筛选。

公开(公告)号：US09333194B2

公开(公告)日：2016-05-10

申请号：US12504823

申请日：2009-07-17

申请人： Masayoshi Shichiri ,  Yujiro Tanaka

发明人： Masayoshi Shichiri ,  Yujiro Tanaka

IPC分类号： A61K31/395 ,  A61K31/496 ,  G01N33/50

CPC分类号： A61K31/395 ,  A61K31/496 ,  G01N33/5011

摘要： The present invention provides novel angiogenesis inhibitors effective, safe and highly practical for inhibition of angiogenesis in various diseases, and a method for screening the same. The active ingredients of the angiogenesis inhibitors of the present invention comprise ansamycin antibiotics such as rifampicin, rifamycin SV and 3-formyl rifamycin, which have long been used extensively as antibacterial agents for treating tuberculosis or Gram-positive bacterial infections. The active ingredients of the present invention have excellent angiogenesis-inhibiting activity. The angiogenesis inhibitor of the present invention is effective for inhibition of angiogenesis in malignant tumors, diabetic retinopathy, retinal angiogenesis, inflammatory diseases, and angiogenesis accompanying cardiovascular remodeling, etc., and can be used as therapeutic agents against each disease, etc. Further, the screening method of the present invention makes it possible to perform an effective screening of angiogenesis-inhibiting substances by detecting angiogenesis-inhibiting signals based on gene expression levels.

摘要翻译： 本发明提供了用于抑制各种疾病中的血管发生的有效，安全和高度实用的新型血管生成抑制剂及其筛选方法。 本发明的血管发生抑制剂的活性成分包括长时久以来被广泛用作治疗结核病或革兰氏阳性细菌感染的抗菌剂的安莎霉素抗生素如利福平，利福霉素SV和3-甲酰基利福霉素。 本发明的活性成分具有优异的血管生成抑制活性。 本发明的血管生成抑制剂对于抑制恶性肿瘤，糖尿病性视网膜病变，视网膜血管生成，炎症性疾病以及伴随心血管重塑等的血管发生等，对于抑制血管生成有效，可用作针对各种疾病的治疗剂等。另外， 通过本发明的筛选方法，可以通过基于基因表达水平检测血管生成抑制信号来进行血管新生抑制物质的有效筛选。

公开(公告)号：US20080267871A1

公开(公告)日：2008-10-30

申请号：US10599479

申请日：2005-04-01

申请人： Masayoshi Shichiri

发明人： Masayoshi Shichiri

IPC分类号： A61K49/00 ,  C07K16/18 ,  C07K14/00 ,  A61K38/17 ,  A61P9/10 ,  C12N15/64 ,  C07H21/04 ,  C12N5/06

CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K16/26 ,  C07K16/40

摘要： [Object] The present invention is to provide a novel peptide having a potent hypotensive activity by inhibiting cardiac contractility, a DNA encoding the peptide, an antibody against the peptide, or a cardioinhibitory/hypotensive agent comprising the peptide as an active ingredient. A search of a genetic data base revealed the presence of a peptide biosynthesized by a processing of unspliced product of TOR2A mRNA. As a result of functional analysis, a peptide hormone exerting a potent bioactivity and expressed abundantly throughout human organs was found. The peptide is hydrophobic with a molecular weight of 2664.02 consisting of 24 amino acids (AIFIFISNTGGKQINQVALEAWRS) and shows a negative inotropism in rat hearts, as well as a marked systemic hypotensive activity.

摘要翻译： 本发明提供一种通过抑制心脏收缩力具有有效的降血压活性的新型肽，编码该肽的DNA，针对该肽的抗体或包含该肽作为活性成分的心脏抑制剂/降血糖药。 遗传数据库的搜索揭示了通过加工未被切割的TOR2A mRNA产物生物合成的肽的存在。 作为功​​能分析的结果，发现发挥强大生物活性并在人体器官中丰富表达的肽激素。 该肽是疏水性的，分子量为2664.02，由24个氨基酸组成（AIFIFISNTGGKQINQVALEAWRS），并且在大鼠心脏中显示出负的正性，以及显着的全身性降血压活性。

公开(公告)号：US07829526B2

公开(公告)日：2010-11-09

申请号：US10599479

申请日：2005-04-01

申请人： Masayoshi Shichiri

发明人： Masayoshi Shichiri

IPC分类号： C07K14/00 ,  A61K49/00 ,  C07H21/04

CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K16/26 ,  C07K16/40

摘要： The present invention is to provide a novel peptide having a potent hypotensive activity by inhibiting cardiac contractility, a DNA encoding the peptide, an antibody against the peptide, or a cardioinhibitory/hypotensive agent comprising the peptide as an active ingredient. A search of a genetic data base revealed the presence of a peptide biosynthesized by a processing of unspliced product of TOR2A mRNA. As a result of functional analysis, a peptide hormone exerting a potent bioactivity and expressed abundantly throughout human organs was found. The peptide is hydrophobic with a molecular weight of 2664.02 consisting of 24 amino acids (AIFIFISNTGGKQINQVALEAWRS; SEQ ID NO.: 2) and shows a negative inotropism in rat hearts, as well as a marked systemic hypotensive activity.

摘要翻译： 本发明提供通过抑制心脏收缩力具有有效的降血压活性的新型肽，编码肽的DNA，针对肽的抗体或包含该肽作为活性成分的心脏抑制剂/降血糖药。 遗传数据库的搜索揭示了通过加工未被切割的TOR2A mRNA产物生物合成的肽的存在。 作为功​​能分析的结果，发现发挥强大生物活性并在人体器官中丰富表达的肽激素。 该肽是疏水性的，分子量为2664.02，由24个氨基酸组成（AIFIFISNTGGKQINQVALEAWRS; SEQ ID NO：2），并且显示出大鼠心脏中的负性倾向，以及显着的全身性降血压活性。

公开(公告)号：US20110165173A1

公开(公告)日：2011-07-07

申请号：US12599732

申请日：2008-05-09

申请人： Takuya Watanabe ,  Masayoshi Shichiri

发明人： Takuya Watanabe ,  Masayoshi Shichiri

IPC分类号： A61K39/395 ,  A61K38/16 ,  G01N33/68 ,  C07K14/435 ,  C07K16/00 ,  A61P9/10

CPC分类号： A61K38/1709 ,  A61K49/0004 ,  C07K14/575 ,  C07K16/40 ,  G01N33/6893 ,  G01N2800/323

摘要： The present invention provides a prophylactic and therapeutic agent for arteriosclerotic diseases and a method or reagent for detecting arteriosclerotic diseases. Further, the present invention provides a therapeutic agent for an arteriosclerotic disease, comprising salusin-α as an active ingredient, a therapeutic agent for an arteriosclerotic disease, comprising an antagonist of salusin-β as an active ingredient, and a method for detecting an arteriosclerotic disease, comprising assaying salusin-α in a biological sample.

摘要翻译： 本发明提供了用于动脉硬化疾病的预防和治疗剂以及用于检测动脉硬化性疾病的方法或试剂。 此外，本发明提供一种动脉硬化性疾病的治疗剂，其包含salusin-α作为活性成分，用于动脉硬化疾病的治疗剂，其包含salusin-bgr的拮抗剂; 作为活性成分，以及检测动脉硬化性疾病的方法，包括测定生物样品中的salusin-α。

公开(公告)号：US20120322988A1

公开(公告)日：2012-12-20

申请号：US13509150

申请日：2010-11-12

申请人： Masayoshi Shichiri

发明人： Masayoshi Shichiri

IPC分类号： C07K16/12 ,  C07K1/00

CPC分类号： C07K16/1271 ,  A61K2039/505

摘要： The present invention provides a therapeutic agent for psoriasis or atopic dermatitis, and comprises anti-Staphylococcus aureus antibodies as the active ingredient. A therapeutic agent for psoriasis or atopic dermatitis is specifically provided. This agent comprises comprehensive anti-S. aureus surface antibodies, including antibodies against entire cell-surface proteins, as the active ingredient. The agent is obtainable by: (a) treating S. aureus with a protein crosslinking/fixation reagent to fix proteins expressed on the surface of S. aureus via intramolecular crosslinking; (b) administering S. aureus treated with the protein crosslinking/fixation reagent for protein fixation to an animal as an immunogen; and (c) obtaining an antibody from the animal.

摘要翻译： 本发明提供了用于牛皮癣或特应性皮炎的治疗剂，并且包含抗金黄色葡萄球菌抗体作为活性成分。 专门提供牛皮癣或特应性皮炎的治疗剂。 这个代理商包括全面的反S。 金黄色葡萄球菌表面抗体，包括针对整个细胞表面蛋白的抗体，作为活性成分。 该试剂可通过以下方法获得：（a）用蛋白质交联/固定试剂处理金黄色葡萄球菌以通过分子内交联固定在金黄色葡萄球菌表面上表达的蛋白质; （b）将用用于蛋白质固定的蛋白质交联/固定剂处理的金黄色葡萄球菌作为免疫原施用于动物; 和（c）从动物获得抗体。

公开(公告)号：US20120164135A1

公开(公告)日：2012-06-28

申请号：US13141009

申请日：2009-12-18

申请人： Masayoshi Shichiri ,  Yasuhiro Ii ,  Ikuko Ii ,  Kentaro Ii ,  Daisuke Ii ,  Maiko Ii

发明人： Masayoshi Shichiri ,  Yasuhiro Ii ,  Ikuko Ii ,  Kentaro Ii ,  Daisuke Ii ,  Maiko Ii

IPC分类号： A61K39/395 ,  A61P31/00 ,  C07K16/00

CPC分类号： C07K16/1203 ,  A23K20/10 ,  A23K20/195 ,  A23K50/80 ,  A23L33/17 ,  A61K2039/505 ,  C07K2317/11 ,  C07K2317/23

摘要： A method for preparing comprehensive antibodies against whole proteins that are expressed on the surface of a microorganism and the comprehensive antibodies obtained by the method are provided. The method for preparing comprehensive antibodies against whole proteins that are expressed on the surface of a microorganism comprises: (a) treating a microorganism with a protein crosslinking and immobilization reagent and thus immobilizing proteins expressed on the surface of the microorganism via intramolecular crosslinking; (b) administering the microorganism as an immunogen immobilized using the protein crosslinking and immobilization reagent to an animal; and (c) obtaining antibodies from the animal.

摘要翻译： 提供了一种制备在微生物表面表达的全蛋白的综合抗体的方法和通过该方法获得的综合抗体。 用于制备在微生物表面表达的全蛋白的综合抗体的方法包括：（a）用蛋白质交联和固定试剂处理微生物，从而通过分子内交联固定表达在微生物表面上的蛋白质; （b）使用蛋白质交联和固定化试剂将动物作为免疫原给予微生物; 和（c）从动物获得抗体。

公开(公告)号：US20110151485A1

公开(公告)日：2011-06-23

申请号：US13060753

申请日：2009-08-24

申请人： Masayoshi Shichiri

发明人： Masayoshi Shichiri

IPC分类号： G01N33/53

CPC分类号： G01N33/5064

摘要： Disclosed are a method for screening for an antiangiogenic agent and a method for screening for an antiangiogenic gene, both of which are achieved by detecting an antiangiogenic signal within a short time by a simple means. The method for screening for an antiangiogenic agent comprises: a candidate compound administration step of administering a candidate compound for the antiangiogenic agent to a vascular endothelial cell or a cultured cell derived from a vascular endothelial cell; a cell-maintaining step of maintaining the vascular endothelial cell or the cultured cell derived from the vascular endothelial cell to which the candidate compound has been administered; and a signal detection step of detecting the phosphorylation of a protein phosphorylated by the administration of endostatin.

摘要翻译： 公开了用于筛选抗血管生成剂的方法和用于筛选抗血管生成基因的方法，这两者均通过简单的方法在短时间内检测抗血管生成信号来实现。 筛选抗血管生成剂的方法包括：向血管内皮细胞或来自血管内皮细胞的培养细胞施用抗血管生成剂的候选化合物的候选化合物给药步骤; 维持血管内皮细胞或源自已经施用候选化合物的血管内皮细胞的培养细胞的细胞维持步骤; 以及检测通过施用内皮抑制素磷酸化的蛋白质的磷酸化的信号检测步骤。